[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362993-105":59,"doc-detail-362993-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","does-cannabinoid-use-reduce-opioid-utilization-among-patients-with-gastrointestinal-cancer-evidence-from-epic-cosmos","Does Cannabinoid Use Reduce Opioid Utilization Among Patients with Gastrointestinal Cancer - Evidence from Epic COSMOS","","Whether medical cannabis reduces opioid use during early chemotherapy remains unclear. This study evaluates cannabinoid and opioid prescribing among patients with gastrointestinal (GI) cancers initiating chemotherapy between 2016 and 2025 using the Epic COSMOS database. Cannabis exposure was based on EHR prescriptions for FDA-approved cannabinoids. After exclusions for prior cannabis/opioid use and early death, multivariable logistic regression assessed factors linked to cannabinoid use. Among 144,981 patients, 2.4% received cannabinoids within 90 days, and early cannabinoid prescribing was not associated with reduced opioid use.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/does-cannabinoid-use-reduce-opioid-utilization-among-patients-with-gastrointestinal-cancer-evidence-from-epic-cosmos/362993/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/does-cannabinoid-use-reduce-opioid-utilization-among-patients-with-gastrointestinal-cancer-evidence-from-epic-cosmos/362993.png","ImageObject",300,407,{"name":92,"@type":93},"Putri","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main purpose of this study?","Question",{"text":112,"@type":113},"To determine whether cannabinoid use during early chemotherapy is associated with reduced opioid use among patients with gastrointestinal cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the study define cannabinoid exposure?",{"text":117,"@type":113},"Cannabis exposure was defined as prescriptions for FDA-approved cannabinoids recorded in the EHR; non-prescription cannabis from dispensaries was not captured.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show about opioid use?",{"text":121,"@type":113},"Early cannabinoid prescribing was not associated with reduced opioid use early in treatment, despite differences in who received cannabinoids.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362993,1790248008,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},962085571259,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Article  \nDoes Cannabinoid Use Reduce Opioid Utilization Among Patients with Gastrointestinal Cancer? Evidence from Epic COSMOS  \nEshetu B. Worku, Selamawit A. Woldesenbet and Timothy M. Pawlik *  \nAcademic Editor: Yusuke Shiozawa  \nReceived: 20 February 2026  \nRevised: 25 March 2026  \nAccepted: 26 March 2026  \nPublished: 30 March 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nDepartment of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH 43210, USA; [eshetu.worku@osumc.edu](eshetu.worku@osumc.edu) (E.B.W.);  \n[selamawit.woldesenbet@osumc.edu](selamawit.woldesenbet@osumc.edu) (S.A.W.)  \n* Correspondence: [tim.pawlik@osumc.edu](tim.pawlik@osumc.edu); Tel.: +1-614-293-8701  \nSimple Summary  \nPatients with gastrointestinal (GI) cancers receiving chemotherapy often experience difficult symptoms such as pain, nausea, reduced appetite, and fatigue. As cannabis use has expanded across the United States, many have questioned whether it could help to manage these symptoms while also reducing reliance on opioid medications, which carry risks of dependence and overdose. Despite increasing interest, it remains unclear whether cannabis use leads to lower opioid use in cancer care. This study examined real-world prescribing patterns of cannabinoids and opioids in a large national database of patients starting chemotherapy. We aimed to understand which patients receive cannabis, how prescribing varies by region or patient characteristics, and whether cannabis use is associated with reduced opioid use early in treatment. Our findings show that cannabis prescribing remains relatively uncommon and was not linked to lower opioid use. These results underscore the need for additional research to guide safe, effective, and equitable symptom management for people undergoing cancer treatment.  \nAbstract  \nPurpose: Whether medical cannabis reduces opioid use during early chemotherapy remains unclear. We examined cannabinoid and opioid prescribing among patients with GI cancers initiating chemotherapy. Methods: Patients with GI cancers initiating chemotherapy (2016–2025) were identified from the Epic COSMOS database. Cannabis exposure was defined as prescriptions for FDA-approved cannabinoids recorded in the EHR; non-prescription cannabis obtained through dispensaries were not captured. Patients with any cannabis or opioid use in the prior year or death within 90 days were excluded. Multivariable logistic regression evaluated factors associated with cannabinoid use. Results: Among 144,981 patients, 2.4% received cannabinoids within 90 days of chemotherapy initiation. Cannabinoid recipients were more likely to receive opioids than nonrecipients (60.6% vs. 31.1%, p \u003C 0.01) . In adjusted analyses, cannabinoid prescribing was more common among Black patients (aOR 1.45; 95%CI 1.30–1.61), women (aOR 1.11; 95%CI 1.03–1.19), and individuals with pancreatic cancer (aOR 3.26; 95%CI 2.97–3.58) . Prescribing varied by region and declined over time, relative to 2017 . Conclusions: Early cannabinoid prescribing was not associated with reduced opioid use. Use was more common among patients with pancreatic cancer and among Black patients, highlighting clinical and structural variation in supportive-care practices.  \nKeywords: cannabis; cannabinoids; opioids; GI cancer; chemotherapy; COSMOS  \n1. Introduction  \nOver the past two decades, cannabis use in the United States has increased substantially, driven by state-level medical and recreational legalization and growing public acceptance [1–4] . As of 31 December 2025, medicinal cannabis is permitted in 47 states and Washington, DC, and recreational use is legal in 24 states [5] . Concurrently, cannabis is increasingly considered for symptom management (pain, nausea, vomiting, appetite loss, sleep ","cbCaiaS1DN1LsktK","https://ap.wps.com/l/cbCaiaS1DN1LsktK","pdf",732470,12,"English","# Simple Summary\n# Abstract\n# 1. Introduction","[{\"question\":\"What was the main purpose of this study?\",\"answer\":\"To determine whether cannabinoid use during early chemotherapy is associated with reduced opioid use among patients with gastrointestinal cancer.\"},{\"question\":\"How did the study define cannabinoid exposure?\",\"answer\":\"Cannabis exposure was defined as prescriptions for FDA-approved cannabinoids recorded in the EHR; non-prescription cannabis from dispensaries was not captured.\"},{\"question\":\"What did the results show about opioid use?\",\"answer\":\"Early cannabinoid prescribing was not associated with reduced opioid use early in treatment, despite differences in who received cannabinoids.\"}]","Does Cannabinoid Use Reduce Opioid Utilization Among Patients with Gastrointestinal Cancer - Evidence from Epic COSMOS | PDF",1790149606,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/57a2868e39a0fcf271e010aadc205134.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/50e1a9b001fb6249538f68ad5b75612f.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8c7bed1e35f1ebb38a98b50f78318855.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c18c55baf671d87607bc9e08ef532c7c.webp",980,1385]